Nasdaq News

Key PointsTilray’s financial results have been weak for years.

Key PointsThe Nasdaq-100 has climbed 20% or more for three calendar years straight, starting with a 54% gain in 2023.

Key PointsThe executive purchased 96,702 shares for a total consideration of $1.7 million.

Key PointsCrowdStrike continues to dominate the cybersecurity market with its integrated Falcon platform.

Key PointsThanks to its massive ecosystem, Meta can indirectly generate ad revenue through its popular Muse AI agent.

The S&P 500 Index ($SPX ) (SPY ) closed up by +0.59% on Friday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +0.83%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.51%. December E-mini S&P futures (ESZ26 ) rose +0.59%, and December E-mini...

Key PointsNike's performance in October this decade has been a mixed bag.

Key PointsThe iShares U.S. Pharmaceuticals ETF is significantly more concentrated than the State Street SPDR S&P Pharmaceuticals ETF, with Eli Lilly accounting for 23.63% of the portfolio.

Key PointsSpaceX’s AI losses are erasing Starlink’s profits.

Key PointsThe average man's Social Security benefit was $2,282.28 as of December 2025.

Key PointsJoby completed a 3,199-mile autonomous flight with zero pilot inputs.

Key PointsAdvanced Micro Devices is leveraging strategic partnerships with industry leaders to expand its footprint in the high-performance data center market.

Key PointsBitcoin ETFs have seen significant inflows in recent weeks.

Key PointsDutch Bros grew Q2 revenue by 32% to $551 million, with same-shop sales up 8.3%, driven by real transaction growth rather than higher prices.

Key PointsNEAR Protocol is up more than 230% for the year, making it a standout crypto performer in 2026.

SoundHound AI (NASDAQ: SOUN) has a much larger enterprise opportunity after acquiring LivePerson. The critical question is whether OASYS can turn that expanded customer reach into cross-selling, higher recurring revenue, and improved economics before losses, declining legacy reve

Key PointsThe VanEck Biotech ETF and State Street SPDR S&P Pharmaceuticals ETF both carry an identical expense ratio of 0.35%.

Key PointsViking Therapeutics will soon enter phase 3 trials with its weight loss pill candidate.

Key PointsBristol Myers Squibb provides high free cash flow and a deep oncology pipeline at a modest valuation.

Key PointsAST generates all of its revenue from defense contracts and commercial prepayments rather than continuous commercial contracts.